

BIBLIOGRAFIA

[1] <http://www.spread.it>;

[2] Sacco S, Di Gianfilippo G, Di Napoli M, Santalucia P, Euforbio M, Triggiani L et al. Risultati a 5 anni de L'Aquila Stroke Registry (1994-1998) e confronto con studi comparabili di popolazioni nazionali ed internazionali per una politica di gestione programmata della patologia. *Rivista Italiana di Neurobiologia*, 2006; 2: 109-136;

[3] Sarti C, Rastenyte D, Cepatis Z, Tuomilehto J. International trends in mortality from stroke. *Stroke* 2000; 31: 1588-1601;

[4] Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? *Lancet*, 2005; 366: 1578-1582;

[5] Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. *Lancet* 2003; 362: 1211-1224;

[6] Fitzpatrick M, Birus J. Thrombolysis for acute ischemic stroke and the role of the nurse. *British journal of nursing*, 2004; 13: 1170-1174;

[7] Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. *Neurology*, 2004; 62: 77-81;

[8] <http://www.ionio.cineca.it/>;

[9] Innes K, Rycarte J, Day D, Aitcheson S, Beattie P, Hunter A et al. Thrombolysis for acute ischaemic stroke: core nursing requirements. *British journal of nursing*, 2003; 7: 416-423;

[10] <http://www.istat.it/sanit /Health>;

[11] <http://www.ares.piemonte.it>;

[12] Lawrence M, Kerr S, Watson HE, Jackson J, Brownlee MG. A summary of the guidance relating to four lifestyle risk factors for recurrent stroke. *British journal of neuroscience nursing*, 2009; 5:471-476;

[13] Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Stroke*, 2001; 32: 280-99;

[14] Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ*, 2004; 328: 1519-1528;

[15] He FJ, Mac Gregor G. Reducing population salt intake worldwide: from evidence to implementation. *Progress in cardiovascular diseases*, 2010: 363-382;

[16] Carpenito-Moyet LJ, Diagnosi infermieristiche. Milano, Casa Editrice Ambrosiana, terza edizione, 2006;

[17] Spairani C, Raganini G, Nursing in neurologia: l'assistenza infermieristica al paziente con ictus. Roma, Carocci Faber, 2003;

[18] Engelter S, Gostynski M, Papa S, Frei M, Born C, Gutzwiller F et al.; Epidemiology of aphasia attributable to first ischemic stroke: incidence, severity, fluency, etiology, and thrombolysis; *Stroke*, 2006; 37: 1379-1384;

[19] Rose KM, Rosamond W, Huston S, Murphy C, Tegeler C. predictors of time from hospital arrive to initial Brain-Imaging among suspected stroke patients: the north Carolina collaborative stroke registry. *Stroke* 2008; 39: 3262-3267;

[20] Nota già citata n. 1;

[21] Angelelli P, Paolucci S, Bivona U, Piccardi L, Ciurli P, Cantagallo A. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. *Acta Psychiatr Scand*, 2004; 110: 55-63;

[22] Nota già citata n. 1, 20;

[23] Nota già citata n. 17;

[24] Rosevinge SK, Starke ID. Improving care for patients with dysphagia. *Age and ageing*, 2005; 34: 587-593;

[25] Elpern EH, Killen K, Ketchem A, Wiley A, Patel G, Lateef O et al. Reducing use of indwelling urinary catheters and associated urinary tract infections. *American journal of critical care*, 2009; 18: 535-542;

[26] Jorgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population control: depressive symptoms predict falls after stroke. *Stroke* 2002; 33: 542-547;

[27] Schmid AA, Rittman M. Consequences of poststroke falls: activity limitation, increase dependence, and the development of fear of falling. *The American journal of occupational therapy*, 2009; 63: 310-315;

[28] <http://www.thelancet.com>;

[29] The National institute of neurological disorders and rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J med*, 1995; 333: 1581-1587;

[30] Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R et al. safety and efficacy of intravenous thrombolysis with a recombinant tissue plasminogen

activator in the treatment of acute hemispheric stroke. *JAMA* 1995; 274: 1017-1025;

[31] Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D et al. Randomized double-blind placebo-controller trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. *Lancet*, 1998; 352: 1245-1251;

[32] Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptoms onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for noninterventional therapy in ischemic stroke. *JAMA*, 1999; 282: 2019-2026;

[33] Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N et al. Stroke treatment with Alteplase give 3-4,5 hours after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomized controlled trial. *Lancet*, 2009; 8: 1074-1075;